Welcome to VIRTTU
VIRTTU Biologics is a clinical stage biotechnology company pioneering the development of oncolytic immunotherapies to treat cancer.
By remodelling a common Herpes Simplex virus (HSV) we have developed and patented a series of novel agents that target many forms of cancer effectively and have the potential to transform treatment.
SEPREHVIR®, our most advanced programme, is a unique cancer-destroying oncolytic immunotherapy that has the potential to radically change cancer therapy through its ability to:
(i) seek out and multiply only in cancer cells, destroying them while leaving healthy cells unaffected and;
(ii) stimulate a long lasting anti-tumour immune response.
We are now actively advancing the clinical development programme required to secure regulatory approval to market our lead programme, SEPREHVIR®, for use in cancer therapy.
In parallel, VIRTTU has an exciting development pipeline of next-generation oncolytic immunotherapies which build on the SEPREHVIR® concept by engineering additional therapeutic genes into the SEPREHVIR® backbone.
Better Together in Oncolytic Immunotherapy: the immune response is key for oHSV efficacy
Research team shows immune response is critical for oncolytic HSV efficacy in tumor models. The research has implications for cancer treatment and the development of oncolytic immunotherapy. In some patients, even limited viral infection of the tumour cells by oncolytic oHSV virus may be sufficient to stimulate their immune system to attack the tumour cells.